NLRP3 Inflammasome Assembly Project

SCOPING BIOLOGY_DOMAINFLAGSHIP

Species: human

NLRP3 Inflammasome Assembly Project

Bottom line: the NLRP3 inflammasome is a danger-sensing complex in which
the sensor NLRP3 recruits the adaptor PYCARD (ASC) to activate caspase-1, which
matures IL-1β and IL-18 and cleaves gasdermin D to open pyroptotic pores.
Scoped, with the pathway now modelled: this page lists ten candidate human genes
and the pathway architecture, and the assembly chain has been built as
canonical NLRP3 inflammasome,
a seven-part module (NLRP3 sensor activation → optional NEK7 licensing → ASC
speck → caspase-1 autoprocessing → caspase-1 substrate cleavage → GSDMD pore →
NINJ1 rupture) built from the NLRP3, PYCARD, CASP1, NEK7, GSDMD and NINJ1 gene
reviews and aligned with GO-CAMs
gomodel:635b1e3e00001811 and
gomodel:663d668500001246.
Three candidates already had complete reviews from other work (NLRP3,
CASP4 and GSDMD, 364 annotations between them; most removals are generic
protein binding rows, 24 of 25 on NLRP3), and the NLRP3 review proposes a
new GO term, inflammasome sensor activity, because GO:0140299 molecular
sensor activity requires binding the sensed molecule. The adaptor PYCARD, the effector
CASP1 and the licensing kinase NEK7 have since been reviewed (PR #4536); CASP5,
IL1B, IL18 and BRCC3 still have no gene folder. The draft
metazoan NLR signaling module keeps NLRP3,
PYCARD and CASP1 as a compact pathway-level view alongside the NOD2–RIPK2
branch; the mechanistic detail now lives in the dedicated inflammasome module.

We scoped this because NLRP3 is a major therapeutic target and drives
autoinflammatory disease (CAPS) and inflammation in gout, atherosclerosis and
Alzheimer disease, and recent work on activation sites, post-translational
control and structure is likely to be under-represented in GO.

Overview

The NLRP3 inflammasome is a multiprotein complex that activates inflammatory caspases in response to diverse danger signals, leading to IL-1β/IL-18 release and pyroptotic cell death. Recent discoveries have clarified activation mechanisms and identified new regulators.

Model Species

Primary: Homo sapiens (human)
- Major therapeutic target
- Autoinflammatory disease relevance

Core Pathway Architecture

1. Sensor

2. Adaptor

3. Effector Caspases

4. Substrates/Outputs

5. Critical Regulators

6. Priming/Licensing

Candidate Genes (~12-15)

Gene UniProt Function
NLRP3 Q96P20 Sensor
PYCARD Q9ULZ3 ASC adaptor
CASP1 P29466 Effector caspase
CASP4 P49662 Non-canonical
CASP5 P51878 Non-canonical
GSDMD P57764 Pore formation
IL1B P01584 Cytokine
IL18 Q14116 Cytokine
NEK7 Q8TDX7 Essential activator
BRCC3 P46736 Deubiquitinase

Mechanism as currently modelled

Reconciled against PMID:41062723
(Dubey et al., Cell Mol Immunol 2025, "Molecular mechanisms and regulation of
inflammasome activation and signaling") and the primary structural literature it
cites. Details and evidence quotes are in
the module.

Other inflammasomes in the review (not modelled here)

PMID:41062723 also covers NLRP1, NLRP6, NLRP7, NLRP9, NLRP10, NLRP12,
NAIP–NLRC4, AIM2, Pyrin, IFI16, CARD8 and MxA. Two patterns matter for future
modelling:

Disease Relevance

Modules

Project Status